Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Antony A, Holland R, Mokkink W, D’agostino MA, Maksymowych WP, Bertheussen H, Schick L, Goel N, Ogdie A, Orbai AM, Hoejgaard P, Coates LC, Strand V, Gladman DD, Christensen R, Leung YY, Mease PJ, Tillett W. AB0737 MEASUREMENT PROPERTIES OF RADIOGRAPHIC OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW FROM THE GRAPPA-OMERACT INITIATIVE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2431] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]

For:	Antony A, Holland R, Mokkink W, D’agostino MA, Maksymowych WP, Bertheussen H, Schick L, Goel N, Ogdie A, Orbai AM, Hoejgaard P, Coates LC, Strand V, Gladman DD, Christensen R, Leung YY, Mease PJ, Tillett W. AB0737 MEASUREMENT PROPERTIES OF RADIOGRAPHIC OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW FROM THE GRAPPA-OMERACT INITIATIVE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2431] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]

Number

Cited by Other Article(s)

Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, Ogle K, Reveille JD, Winthrop KL, Choi D. The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. J Rheumatol 2021;49:225-229. [PMID: 34599048 DOI: 10.3899/jrheum.210742] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/23/2021] [Indexed: 11/22/2022]

Affiliation(s)

James T Rosenbaum This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Michael H Weisman This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Hedley Hamilton This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Cassie Shafer This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Elin Aslanyan This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Richard A Howard This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Kimberly Ogle This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
John D Reveille This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Kevin L Winthrop This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021
Dongseok Choi This work was supported by the Spondylitis Association of America and Any-3. The Spondylitis Association of America receives support from AbbVie for this project. AbbVie played no role in the study design, data interpretation, or writing of the results. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. J.T. Rosenbaum, MD, Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, and Legacy Devers Eye Institute, Portland, Oregon, USA; M.H. Weisman, MD, Cedars Sinai Medical Center, Los Angeles, California, USA; H. Hamilton, BSc, Any-3, London, UK; C. Shafer, BS, E. Aslanyan, BA, R.A. Howard, BA, Spondylitis Association of America, Los Angeles, California, USA; K. Ogle, BA, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; J.D. Reveille, MD, Department of Medicine, University of Texas, Houston, Texas, USA; K.L Winthrop, MD, MPH, D. Choi, PhD, OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; receives royalties from UpToDate; and receives grant support from Pfizer and Horizon. JTR serves on a data monitoring committee for Celgene (BMS). HH owns Any-3, the website that hosted the survey and donated its services. RAH owns stock in AbbVie, Amgen, BMS, GSK, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; and receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; and receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no conflicts of interest relevant to this article. Address correspondence to Dr. J.T. Rosenbaum, Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L467Ad Portland, OR 97239, USA. . Accepted for publication September 23, 2021

Collapse

Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, El Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021;7:e001814. [PMID: 34493645 PMCID: PMC8424419 DOI: 10.1136/rmdopen-2021-001814] [Citation(s) in RCA: 105] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 08/18/2021] [Indexed: 12/13/2022] Open

Affiliation(s)

Sebastian Eduardo Sattui Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA
Jean W Liew Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
Kevin Kennedy Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
Emily Sirotich Medicine, McMaster University, Hamilton, Ontario, Canada
Michael Putman Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Tarin T Moni Department of Biochemistry & Biomedical Sciences, McMaster University Faculty of Science, Hamilton, Ontario, Canada
Akpabio Akpabio Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Deshiré Alpízar-Rodríguez Research Unit, Mexican College of Rheumatology, Coyoacan, Ciudad de México, Mexico
Francis Berenbaum Rheumatology, Sorbonne Université, Paris, France
Inita Bulina Department of Internal Diseases, Rheumatology Centre, Paul Stradins Clinical University Hospital, Riga, Latvia
Richard Conway Rheumatology, Saint James's Hospital, Dublin, Ireland
Aman Dev Singh Community Medicine, GMC Patiala, Punjab, India
Eimear Duff Department of Rheumatology, Saint James's Hospital, Dublin, Ireland
Karen L Durrant Autoinflammatory Alliance, San Francisco, California, USA
Tamer A Gheita Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt
Catherine L Hill Rheumatology Department, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia
Richard A Howard Spondylitis Association of America, Van Nuys, California, USA
Bimba F Hoyer Medical Department I, Department for Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany
Evelyn Hsieh Section of Rheumatology, Allergy & Immunology, Yale School of Medicine, New Haven, Connecticut, USA Section of Rheumatology, VA Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, USA
Lina El Kibbi Rheumatology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia
Adam Kilian Department of Internal Medicine, Division of Rheumatology, Saint Louis University, Saint Louis, Missouri, USA
Alfred Hyoungju Kim Medicine/Rheumatology, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA
David F L Liew Rheumatology, Austin Health, Heidelberg West, Victoria, Australia Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia
Chieh Lo I-Shou University College of Medicine, Yanchau Sheng, Taiwan
Bruce Miller Medicine, University of California San Diego, La Jolla, California, USA
Serena Mingolla Italian National Patient Association for Rehumatoid and Rare Disease (APMARR), Rome, Italy
Michal Nudel The Israeli Association for RMD Patients "Mifrakim Tz'eirim", Haifa, Israel
Candace A Palmerlee Relapsing Polychondritis Foundation, International Relapsing Polychondritis Research Network, Walnut Creek, California, USA
Jasvinder A Singh Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
Namrata Singh Medicine, Division of Rheumatology, University of Washington, Seattle, Washington, USA
Manuel Francisco Ugarte-Gil Department of Rheumatology, Universidad Cientifica del Sur, Lima, Peru Universidad Científica del Sur, Lima, Peru
John Wallace Autoinflammatory UK, Edinburgh, UK
Kristen J Young Division of Rheumatology, University of Texas Southwestern Medical School, Dallas, Texas, USA
Suleman Bhana Crystal Run Healthcare, Middletown, New York, USA
Wendy Costello Irish Children's Arthritis Network (iCAN), Tipperary, Ireland
Rebecca Grainger Department of Medicine, Malaghan Institute of Medical Research, Wellington, New Zealand
Pedro M Machado MRC Centre for Neuromuscular Diseases, University College London, London, UK Rheumatology, University College London Centre for Rheumatology, London, UK
Philip C Robinson Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia
Paul Sufka Healthpartners, St Paul, Minnesota, USA
Zachary S Wallace Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology,Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Jinoos Yazdany Medicine/Rheumatology, University of California, San Francisco, California, USA
Carly Harrison LupusChat, New York, New York, USA
Maggie Larché Division of Clinical Immunology and Allergy, McMaster University Department of Medicine, Hamilton, Ontario, Canada
Mitchell Levine Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
Gary Foster Department of Health Research Methods, Evidence, and Impact (HEI); Medicine, McMaster University, Hamilton, Ontario, Canada
Lehana Thabane Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
Lisa G Rider Environmental Autoimmunity Group, NIEHS/NIH/DHHS, Bethesda, Maryland, USA
Jonathan S Hausmann Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Julia F Simard Epidemiology and Population Health and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA Department of Medicine, Clinical Epidemiology Unit, Sweden
Jeffrey A Sparks Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA

Collapse

Rosenbaum JT, Weisman MH, Shafer C, Aslanyan E, Howard RA, Ogle K, Hamilton H, Reveille JD, Winthrop KL, Choi D. Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'. Ann Rheum Dis 2021;82:e138. [PMID: 33985940 DOI: 10.1136/annrheumdis-2021-220588] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Accepted: 04/20/2021] [Indexed: 11/04/2022]